Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review
Purpose of the review: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are recommended for eligible patients with type 2 diabetes for the secondary prevention of adverse cardiovascular and kidney disease outcomes. Patients with type 2 diabetes and albuminuric chronic kidney disease, a history of...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-06-01
|
Series: | Canadian Journal of Kidney Health and Disease |
Online Access: | https://doi.org/10.1177/2054358120935701 |